Last reviewed 2026-04-22 · How we verify

Antivipmyn ®

Antivipmyn is an antivenom that neutralizes venom toxins by binding to and inactivating specific venom components through antibody-antigen interactions.

Antivipmyn is an antivenom that neutralizes venom toxins by binding to and inactivating specific venom components through antibody-antigen interactions. Used for Envenomation from venomous snakes and other venomous animals.

At a glance

Mechanism of action

Antivipmyn is a polyvalent antivenom derived from animal serum (typically equine or ovine) that contains antibodies against multiple venom toxins. These antibodies bind to and neutralize the active components of venom, preventing their pathological effects on tissues and organs. It is administered intravenously to treat envenomation from snake or other venomous animal bites.

Approved indications

• Envenomation from venomous snakes and other venomous animals

Common side effects

• Serum sickness
• Hypersensitivity reactions
• Anaphylaxis

Key clinical trials

• Cryotherapy as a Coadjuvant in Crotaline Snakebite Management With Antivenom. (NA)
• Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Antivipmyn ® CI brief — competitive landscape report
• Antivipmyn ® updates RSS · CI watch RSS
• Instituto Bioclon S.A. de C.V. portfolio CI